Taihua (TAIH)

Taihua plc is engaged in the development, production, distribution and sale of active pharmaceutical ingredients, namely paclitaxel and homoharringtonine, predominately for the use in the treatment of cancer and the development, production, distribution and sale of Traditional Chinese Medicine (TCM) products. It operates in three segments: Paclitaxel, Homoharringtonine, TCM products and Forsythia. Paclitaxel is extracted from the bark of the yew tree (Taxus), which is used in the treatments for cancer of the ovaries, breast, certain types of lung cancer, and a cancer of the skin and mucous membranes. Homoharringtonine is an alkaloid extracted from the branches and leaves of the Cephalotaxus tree, which is used for acute myeloid leukaemia and other cancers in China. TCM products include Gengnianan Tablet, Duzhong Pingya Tablet, Zaoren Anshen Keli, Bunao Anshen Tablet, Jiangzi Jianfei Tablet and Dabaidu Capsule. Forsythia is associated with the heart, lung and gall bladder meridians.

Directors: Yunwu Liu (CEO) 54, Chun Chai (Exec. Dir.) 61, Liyi Chen (Exec. Dir.) 51, Zhaoyang Ma (Exec. Dir.) 44,

No. of Employees: 113 No. of Shareholders: n/a

Last Annual	December 31st, 2011
Last Interim	June 30th, 2012
Shares in Issue	81,737,330
Free Float	23.2m (28.4%)

Sector	Healthcare
Industry	Pharmaceuticals
Index	FTSE Aim All Share,
Exchange	London Stock Exchange (AIM)
Eligible for	an ISA? a SIPP?